Category: Case Study

Primary biliary cholangitis (PBC) is a chronic disease that impedes bile flow from the liver, resulting in increased bile acid concentration, which causes cell damage. Untreated PBC can lead to liver failure and death. At the start of this project, the only approved treatment for PBC was not effective for all patients.

A large biopharmaceutical company required insight on the current market access landscape in a rare disease, as well as feedback on a pipeline product that will launch as a second-to-market agent in the rare disease.